A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

Duration of Response (DOR) Based on PET/CT Status

DOR will be calculated as the time (months) from the first documentation of a confirmed CR or PR (whichever is first recorded) to the date of objective PD or death from any cause, whichever is earliest. DOR will be assessed by investigator using 5-point scale for visually assessing response on the pre and end-of-treatment PET/CT scans. The 5-point scale ranges from: 1 (No uptake), 2 (Uptake \<=mediastinum), 3 (Uptake \>mediastinum but \<=liver), 4 (Uptake moderately \>liver), and 5 (Uptake markedly higher than liver and/no new lesions). Total score ranges from 0-5. In case of unavailability of PET/CT scans, DOR will be assessed as per Revised Criteria for Response Assessment for Malignant Lymphoma. Index date: eligible participants who start BV as retreatment.

Time frame: Up to 6 months post-index date or death, whatever come first

Overall Survival (OS)

OS will be calculated as time (months) from the index date (date of initiation of BV as retreatment) to the date of death from any cause or end of follow-up. Participants alive at the end of the study period will be censored. Index date: eligible participants who start BV as retreatment.

Time frame: From the index date to the date of death from any cause or end of follow-up (up to 6 months)

Percentage of Participants With Complete Response Based on PET/CT Status

Complete response will be assessed by investigator using 5-point scale for visually assessing response on the pre and end-of-treatment PET/CT scans. The 5-point scale ranges from: 1 (No uptake), 2 (Uptake \<=mediastinum), 3 (Uptake \>mediastinum but \<=liver), 4 (Uptake moderately \>liver), and 5 (Uptake markedly higher than liver and/no new lesions). Total score ranges from 0-5. In case of unavailability of PET/CT scans, complete response will be assessed as per Revised Criteria for Response Assessment for Malignant Lymphoma. Index date: eligible participants who start BV as retreatment.

Time frame: At the end of retreatment (up to 6 months post-index date or death, whatever come first)

Time to Clinical Response (CR or PR)

Time to clinical response will be calculated from the date of index date (date of initiation of BV as retreatment) to the date of documented CR or PR. Index date: eligible participants who start BV as retreatment.

Time frame: From the index date to the date of documented CR or PR (up to 6 months)

Time to Best Response

Time to best response will be calculated as the time from the index date (date of initiation of BV as retreatment) to first documentation of best response documented. Tumor response will be based on tumour assessments carried out as per local practice. Index date: eligible participants who start BV as retreatment.

Time frame: From the index date to first documentation of best response documented (up to 6 months)

Time to Treatment Failure (TTF)

TTF will be calculated as the time from the index date (date of initiation of BV as retreatment) to first documentation of objective tumor progression or the day of death due to all causes whichever comes earlier. Tumor response will be based on tumour assessments carried out as per local practice. Index date: eligible participants who start BV as retreatment.

Time frame: From the index date to first documentation of objective tumor progression or the day of death due to all causes (up to 6 months)